

ABSTRACT

The present invention relates to the use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or its addition salts with
5 pharmaceutically acceptable acids for the preparation of drugs intended for the treatment of amyotrophic lateral sclerosis (ALS).